BioWorld

July 3, 2007

View Archived Issues

Biogen Pays Cardiokine $50M In Deal On Hyponatremia Drug

Cardiokine Inc. is getting $50 million up front in a potential $220 million deal with Biogen Idec Inc. covering the vasopressin receptor antagonist lixivaptan. (BioWorld Today) Read More

PIPE To Give VIA $25 Million To Push Forward CV Trials

Read More

GSK Passes Up Theravance Stock Buy; Alliance Still Intact

Read More

PSivida Adds $18M In ADS Offering For Ongoing R&D

Read More

Holiday Notice

Read More

Other News To Note

Read More

Clinic Roundup

Read More